Clinical trials: Advanced Solid Cancer
Her2 Amplified Solid Tumors, Metastatic Breast Cancer
A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers
This study is an open-label Phase 1 trial of MM-111.
- Trial name
- Monotherapy (NCT00911898)
- Testing
- MM-111
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Merrimack Pharmaceuticals
Advanced Solid Tumors
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-706 as a monotherapy…
- Trial name
- NCT05599984
- Testing
- ABBV-706, Cisplatin, Budigalimab
- Where
- 66 sites in United States, Australia and 8 more
- Volunteers
- 288 people
- Sponsor
- AbbVie
Advanced Solid Tumor (Phase 1)
Evaluation of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors
This is a first-in-human, non-randomized, open-label, multi-center, phase I study in patients with advanced solid tumor to evaluate the safety and tolerability, PK, immunogenicity, and preliminary anti-tumour activity of T320.
- Trial name
- NCT07434609
- Testing
- T320 for Injection
- Volunteers
- 150 people
- Sponsor
- Nanolattix Biotechnology Co., Ltd.
Non-small Cell Lung Cancer, Gastric Cancer
Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor
Natural killer T (NKT) cells are a unique subset of lymphocytes that present a mixed T-NK phenotype. Our hypothesis is that Natural killer T cells may decrease the tumor burden and improve overall survival.
- Conditions
- Non-small Cell Lung Cancer, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT02562963
- Testing
- natural killer T cell
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Minghui Zhang
Metastatic Castration-resistant Prostate Cancer, Metastatic Prostate Cancer
Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors
The purpose of this study is to evaluate the safety and activity of BPX-601 CAR-T cells in participants with previously treated advanced solid tumors (prostate) expressing high levels of prostate stem cell antigen (PSCA).
- Trial name
- NCT02744287
- Testing
- BPX-601, Rimiducid
- Where
- 13 sites in United States
- Volunteers
- 52 people
- Sponsor
- Regeneron Pharmaceuticals
Solid Tumor, Adult
Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status
A mutilpe-center, open-label, dose-escalation Phase I clinical trial to evaluate the safety and the tolerability of HLX55 in patients with advanced solid tumors overexpressing/Mutation/Amplification cMET after failure of standard…
- Trial name
- NCT04169178
- Testing
- HLX55
- Where
- 4 sites in Taiwan
- Volunteers
- 98 people
- Sponsor
- Henlix, Inc
Advanced Solid Tumours, Breast Cancer
Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours
This is a phase I/II national, multicentre, multiple cohort, prospective open-label, non-randomised and non-comparative study, to evaluate the safety and activity of metronomic oral vinorelbine associated with durvalumab +…
- Conditions
- Advanced Solid Tumours, Breast Cancer, Head and Neck Cancer, Cervix Cancer
- Trial name
- MOVIE (NCT03518606)
- Testing
- Durvalumab + Tremelimumab + metronomic Vinorelbine
- Where
- 9 sites in France
- Volunteers
- 126 people
- Sponsor
- UNICANCER
Solid Tumor
Study of GS-4528 in Adults With Solid Tumors
The goals of this clinical study are to identify if GS-4528 alone or in combination with anti-programmed cell death protein 1 (PD-1) (Anti-PD-1) Monoclonal Antibody is safe and tolerable in people with solid tumors and to…
- Trial name
- NCT05840224
- Testing
- GS-4528, Zimberelimab
- Where
- 16 sites in United States, Canada and 4 more
- Volunteers
- 182 people
- Sponsor
- Gilead Sciences
Solid Tumors
A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors
Study SL-801-0115 is a dose-escalation study evaluating multiple doses and schedules of orally administered SL-801 in participants with advanced solid tumors.
- Trial name
- NCT02667873
- Testing
- SL-801
- Where
- 6 sites in United States
- Volunteers
- 72 people
- Sponsor
- Stemline Therapeutics, Inc.
Solid Tumours
Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer
The purpose of this study is to determine whether AZD1775 has any effect on the pharmacokinetics (PK) of three compounds (caffeine, omeprazole, and midazolam) that are probes for common drug-metabolizing enzymes (caffeine-CYP1A2…
- Trial name
- NCT03333824
- Testing
- CYP1A2 (caffeine), CYP2C19 (omeprazole), CYP3A (midazolam)
- Where
- 7 sites in United States
- Volunteers
- 33 people
- Sponsor
- AstraZeneca
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
This is an open-label, dose-escalation/dose-expansion study of INCB059872 in subjects with advanced malignancies. The study will be conducted in 4 parts.
- Trial name
- NCT02712905
- Testing
- INCB059872, all-trans retinoic acid (ATRA), azacitidine
- Where
- 15 sites in United States, Belgium and 1 more
- Volunteers
- 116 people
- Sponsor
- Incyte Corporation
Epithelial Cancer
Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease
Lapatinib will prevent radiation-induced increase in Transforming Growth Factor alpha (TGFα), an important growth factor in cancer cell recovery after ionizing irradiation.
- Trial name
- NCT01427322
- Testing
- Lapatinib, Radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Virginia Commonwealth University
Unspecified Adult Solid Tumor, Protocol Specific
TNF-Bound Colloidal Gold in Treating Patients With Advanced Solid Tumors
RATIONALE: Biological therapies, such as TNF-bound colloidal gold, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00356980
- Testing
- colloidal gold-bound tumor necrosis factor, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Advanced Solid Tumors
The Primary Objective of This Study to Evaluate the Safety and Tolerability of IBI334 and Determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D)and Anti Tumor Activity of IBI334.
This is open-label, multicenter, Phase I/II study is designed to evaluate the Safety and tolerability and Efficacy of IBI334 Monotherapy in participants with advanced solid tumors.
- Trial name
- NCT05774873
- Testing
- IBI334
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Solid Tumors, Triple-Negative Breast Cancer
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival.
- Conditions
- Solid Tumors, Triple-Negative Breast Cancer, Non Small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT02071862
- Testing
- CB-839, Pac-CB, CBE
- Where
- 13 sites in United States
- Volunteers
- 210 people
- Sponsor
- Calithera Biosciences, Inc
Cancer, Non Small Cell Lung Cancer
Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel
The primary purpose of this study is to explore the safety and tolerability of AZD0530 in combination with carboplatin and paclitaxel in Japanese patients with non small cell lung cancer and epithelial ovarian cancer.
- Conditions
- Cancer, Non Small Cell Lung Cancer, Epithelial Ovarian Cancer
- Trial name
- NCT01000896
- Testing
- AZD0530, Carboplatin, paclitaxel
- Where
- 2 sites in Japan
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Solid Carcinoma
FMT With Nivolumab in Patients With Advanced Solid Cancers Who Have Progressed During Anti-PD-(L)1 Therapy
This is a single-center, open-label, Phase 2 study to evaluate the efficacy and safety of FMT with nivolumab in patients with advanced, unresectable, or metastatic solid cancer who have progressed during anti-PD-(L)1 therapy.
- Trial name
- NIVO-FMT (NCT05533983)
- Testing
- fecal microbiota transplantation with Nivolumab
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Asan Medical Center
Solid Tumors
A Study of HS-20110 in Participants With Advanced Solid Tumors
This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors
- Trial name
- NCT06892379
- Testing
- HS-20110 (Phase Ia：Dose escalation ), HS-20110 (Phase Ib:Dose expansion )
- Where
- 8 sites in United States, China
- Volunteers
- 475 people
- Sponsor
- Hansoh BioMedical R&D Company
Advanced Ovarian Cancer, Primary Peritoneal Cancer
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Background: The poly (ADP-ribose) polymerase (PARP) family of enzymes is critical for maintaining genomic stability by regulating a variety of deoxyribonucleic acid (DNA) damage repair mechanisms.
- Conditions
- Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Breast Cancer, Advanced Solid Tumors
- Trial name
- NCT01989546
- Testing
- BMN 673
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.
This study is being done to learn more about a new drug called Bapotulimab given in combination with Pembrolizumab. The purpose of this study is to learn if this new combination of drugs is safe for the participants, how it…
- Trial name
- NCT03666273
- Testing
- Bapotulimab (BAY1905254), Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®)
- Where
- 8 sites in United States
- Volunteers
- 60 people
- Sponsor
- Bayer
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.